LCTX Stock Chart & Stats
320.80
1.70(0.53%)
At close: 4:00 PM EDT
320.80
1.70(0.53%)
Day’s Range― - ―
52-Week Range305.00 - 666.00
Previous CloseN/A
Volume2.06K
Average Volume (3M)2.66K
Market Cap
₪824.68M
Enterprise Value360.49
Total Cash (Recent Filing)₪53.38M
Total Debt (Recent Filing)₪2.39M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 06, 2026EPS Estimate
-8.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding249,298,300
10 Day Avg. Volume1,735
30 Day Avg. Volume2,664
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)8.63
Price to Sales (P/S)26.40
P/FCF Ratio-19.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₪2,144.06Price Target Upside568.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-20.89
Revenue Forecast (FY)₪4.85B
Bulls Say, Bears Say
Bulls Say
Manufacturing Scale & Platform AdvantageLineage's AlloSCOPE platform demonstrates reproducible tiered banking and an FDA-cleared final product, a durable operational asset. If scale and yield assumptions hold, this lowers per-dose costs, supports off-the-shelf commercial models across indications and creates a lasting manufacturing moat versus bespoke autologous rivals.
Partner Validation & Clinical Durability (OpRegen)Sustained efficacy data and Roche/Genentech's expansion to 17 sites provide durable external validation. Partner commitment de-risks development, creates a defined regulatory/commercial path, and materially increases probability of milestone payments and broader market access versus solo development.
Balance Sheet Flexibility & Multi-Year RunwayReported cash and contingent funding sources provide multi-year runway into 2028 at disciplined spend targets, enabling execution of clinical and manufacturing milestones without immediate equity raises. This financial flexibility supports sustained R&D investment and reduces near-term dilution risk if milestones proceed.
Bears Say
Persistent Negative Cash GenerationTTM negative operating and free cash flows signal ongoing burn that requires recurrent external financing or milestone receipts. Over the medium term this can pressure strategic choices, force dilutive raises, or slow programs if milestone timing slips, weakening financial self-sufficiency.
Deep, Sustained UnprofitabilityExtremely negative margins and losses indicate the business is far from breakeven; continuing R&D and G&A expansion will keep profitability out of reach absent product approvals. This structural loss profile limits the company's ability to internally fund growth and increases dependency on partners and markets.
Islet Program Scale-Up & Manufacturing RiskThe T1D islet program faces fundamental manufacturing scale and differentiation challenges: required cell doses and reactor volumes raise technical and cost hurdles. If AlloSCOPE scale limits or heterogeneity issues persist, commercial production economics and regulatory consistency could be compromised, threatening long-term viability.
Lineage Therap News
LCTX FAQ
What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?
Lineage Cell Therapeutics, Inc. lowest stock price was 305.00 and its highest was 666.00 in the past 12 months.
What is Lineage Cell Therapeutics, Inc.’s market cap?
Lineage Cell Therapeutics, Inc.’s market cap is ₪824.68M.
When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?
Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?
Lineage Cell Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -9.189 earnings per share for the quarter, missing the consensus estimate of -6.126 by -3.063.
Is Lineage Cell Therapeutics, Inc. overvalued?
According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued.
Does Lineage Cell Therapeutics, Inc. pay dividends?
Lineage Cell Therapeutics, Inc. does not currently pay dividends.
What is Lineage Cell Therapeutics, Inc.’s EPS estimate?
Lineage Cell Therapeutics, Inc.’s EPS estimate is -8.58.
How many shares outstanding does Lineage Cell Therapeutics, Inc. have?
Lineage Cell Therapeutics, Inc. has 249,298,300 shares outstanding.
What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?
Lineage Cell Therapeutics, Inc. reported an EPS of -9.189 in its last earnings report, missing expectations of -6.126. Following the earnings report the stock price went down -4.687%.
Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?
Currently, no hedge funds are holding shares in IL:LCTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lineage Therap Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
₪2,144.06 (568.35% Upside)
₪2,144.06 (568.35% Upside)
Blogger Sentiment
Bullish
IL:LCTX Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.99%
Trailing 12-Months
Company Description
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
LCTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial scientific and operational progress across Lineage's manufacturing platform and pipeline: AlloSCOPE advances, the launch and initial preclinical success of COR1, ILT1 scale-up milestones, completed engineering runs for ReSonance, device performance and site expansion for OPC1, SAB and clinical leadership hires, and partner validation for OpRegen (including multi-year vision durability and expansion to 17 sites). Financials show modest revenue, rising R&D and operating expenses, and a larger net loss year-over-year, but a cash runway into 2028 plus potential warrant proceeds and sizeable contingent Roche/Genentech milestones mitigate near-term funding concerns. Program risks remain — notably islet scale-up technical challenges, timing uncertainty tied to partners (OpRegen), and some earlier-stage setbacks (photoreceptor IP change, CIRM non-award) — however the volume and quality of operational and scientific milestones reported suggest progress materially outweighs current financial and program risks.View all IL:LCTX earnings summariesLCTX Stock 12 Month Forecast
Average Price Target
2,144.06
▲(568.35% Upside)
Technical Analysis
Amarin
―
Tvardi Therapeutics
―
DBV Technologies SA - American
―
4D Molecular Therapeutics
―
Aura Biosciences Inc
―